Clinical Trial Update: Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation [Phase 3]

View source ↗

Summary

A pharmacodynamic bioequivalence Phase 3 trial of albuterol sulfate inhalation aerosol was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Asthma

Drugs mentioned

• Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation (albuterol)

Snippet

Sponsor: Aurobindo Pharma Ltd | Conditions: Bronchial Asthma | Phase 3 | Status: WITHDRAWN